<VariationArchive VariationID="225472" VariationName="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs)" VariationType="Deletion" Accession="VCV000225472" Version="55" RecordType="classified" NumberOfSubmissions="18" NumberOfSubmitters="16" DateLastUpdated="2024-06-23" DateCreated="2013-04-04" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="227314" VariationID="225472">
      <GeneList>
        <Gene Symbol="SLC25A13" FullName="solute carrier family 25 member 13" GeneID="10165" HGNC_ID="HGNC:10983" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7q21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96120220" stop="96322098" display_start="96120220" display_stop="96322098" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95749531" stop="95951458" display_start="95749531" display_stop="95951458" Strand="-" />
          </Location>
          <OMIM>603859</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_014251.3(SLC25A13):c.852_855del (p.Met285fs)</Name>
      <CanonicalSPDI>NC_000007.14:96189371:CATAC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>7q21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96189372" stop="96189375" display_start="96189372" display_stop="96189375" variantLength="4" positionVCF="96189371" referenceAlleleVCF="TCATA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95818684" stop="95818687" display_start="95818684" display_stop="95818687" variantLength="4" positionVCF="95818683" referenceAlleleVCF="TCATA" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>851del4</Name>
      </OtherNameList>
      <ProteinChange>M285fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.3" sequenceAccession="NM_014251" sequenceVersion="3" change="c.852_855delTATG" MANESelect="true">
            <Expression>NM_014251.3:c.852_855delTATG</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.2" sequenceAccession="NM_014251" sequenceVersion="2" change="c.852_855delTATG">
            <Expression>NM_014251.2:c.852_855delTATG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.95818685_95818688del" Assembly="GRCh37">
            <Expression>NC_000007.13:g.95818685_95818688del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.96189373_96189376del" Assembly="GRCh38">
            <Expression>NC_000007.14:g.96189373_96189376del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012247.2" sequenceAccession="NG_012247" sequenceVersion="2" change="g.137773_137776del">
            <Expression>NG_012247.2:g.137773_137776del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160210.2" sequenceAccession="NM_001160210" sequenceVersion="2" change="c.852_855del">
            <Expression>NM_001160210.2:c.852_855del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001153682.1" sequenceAccession="NP_001153682" sequenceVersion="1" change="p.Met285fs">
            <Expression>NP_001153682.1:p.Met285fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.3" sequenceAccession="NM_014251" sequenceVersion="3" change="c.852_855del" MANESelect="true">
            <Expression>NM_014251.3:c.852_855del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_055066.1" sequenceAccession="NP_055066" sequenceVersion="1" change="p.Met285fs">
            <Expression>NP_055066.1:p.Met285fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_027662.2" sequenceAccession="NR_027662" sequenceVersion="2" change="n.878_881del">
            <Expression>NR_027662.2:n.878_881del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA253673" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="603859.0001" DB="OMIM" />
        <XRef Type="rs" ID="80338720" DB="dbSNP" />
      </XRefList>
      <GlobalMinorAlleleFrequency Value="0.00080" Source="1000 Genomes Project" MinorAllele="C" />
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND Neonatal intrahepatic cholestasis due to citrin deficiency" Accession="RCV000006368" Version="11">
        <ClassifiedConditionList TraitSetID="1662">
          <ClassifiedCondition DB="MedGen" ID="C1853942">Neonatal intrahepatic cholestasis due to citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-06-30" SubmissionCount="5">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND Citrullinemia type II" Accession="RCV000239614" Version="10">
        <ClassifiedConditionList TraitSetID="1661">
          <ClassifiedCondition DB="MedGen" ID="C1863844">Citrullinemia type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-05-09" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND Citrin deficiency" Accession="RCV000344746" Version="12">
        <ClassifiedConditionList TraitSetID="9638">
          <ClassifiedCondition DB="MedGen" ID="C1997910">Citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-31" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND not provided" Accession="RCV000724667" Version="10">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-07-13" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND Late-onset citrullinemia" Accession="RCV001272102" Version="2">
        <ClassifiedConditionList TraitSetID="64887">
          <ClassifiedCondition DB="MedGen" ID="C0268546">Late-onset citrullinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2020-09-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND Citrullinemia, type II, adult-onset" Accession="RCV002259321" Version="4">
        <ClassifiedConditionList TraitSetID="65850">
          <ClassifiedCondition DB="MedGen" ID="CN295299">Citrullinemia, type II, adult-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-03-30" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND multiple conditions" Accession="RCV002503835" Version="1">
        <ClassifiedConditionList TraitSetID="65625">
          <ClassifiedCondition DB="MedGen" ID="CN295299">Citrullinemia, type II, adult-onset</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1853942">Neonatal intrahepatic cholestasis due to citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-07-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.852_855del (p.Met285fs) AND SLC25A13-related disorder" Accession="RCV003417766" Version="4">
        <ClassifiedConditionList TraitSetID="89115">
          <ClassifiedCondition>SLC25A13-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-12-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-03-30" NumberOfSubmissions="18" NumberOfSubmitters="16" DateCreated="2013-04-04" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10369257</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11281457</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12424587</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12512993</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14680984</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17880783</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19470249</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21424115</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23022256</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23067347</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26852511</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27347070</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27405544</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27577219</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27578510</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">36599957</ID>
        </Citation>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=SLC25A13</URL>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301360</ID>
          <ID Source="BookShelf">NBK1181</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1661" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="973" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia type II</ElementValue>
                <XRef ID="Citrullinemia+Type+II/1652" DB="Genetic Alliance" />
                <XRef ID="MONDO:0016603" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Citrullinemia type 2</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10215" />
                <XRef ID="10215" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="C1863844" DB="MedGen" />
              <XRef ID="MONDO:0016603" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1662" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4809" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neonatal intrahepatic cholestasis due to citrin deficiency</ElementValue>
                <XRef ID="MONDO:0011601" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal intrahepatic cholestasis caused by citrin deficiency</ElementValue>
                <XRef ID="Citrin+Deficiency/1648" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NICCD</ElementValue>
                <XRef Type="MIM" ID="605814" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10214" />
                <XRef ID="10214" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247598" DB="Orphanet" />
              <XRef ID="C1853942" DB="MedGen" />
              <XRef ID="MONDO:0011601" DB="MONDO" />
              <XRef Type="MIM" ID="605814" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="65625" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4809" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neonatal intrahepatic cholestasis due to citrin deficiency</ElementValue>
                <XRef ID="MONDO:0011601" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal intrahepatic cholestasis caused by citrin deficiency</ElementValue>
                <XRef ID="Citrin+Deficiency/1648" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NICCD</ElementValue>
                <XRef Type="MIM" ID="605814" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10214" />
                <XRef ID="10214" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247598" DB="Orphanet" />
              <XRef ID="C1853942" DB="MedGen" />
              <XRef ID="MONDO:0011601" DB="MONDO" />
              <XRef Type="MIM" ID="605814" DB="OMIM" />
            </Trait>
            <Trait ID="55843" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia, type II, adult-onset</ElementValue>
                <XRef ID="MONDO:0011326" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTLN2</ElementValue>
                <XRef Type="MIM" ID="603471" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia_II_Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Citrin Deficiency, Citrullinemia II, Urea Cycle Disorder, 2012</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="CN295299" DB="MedGen" />
              <XRef ID="MONDO:0011326" DB="MONDO" />
              <XRef Type="MIM" ID="603471" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="64887" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="54907" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Late-onset citrullinemia</ElementValue>
              </Name>
              <XRef ID="C0268546" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9638" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6541" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrin deficiency</ElementValue>
                <XRef ID="MONDO:0016602" DB="MONDO" />
                <XRef ID="429735007" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="20661" />
                <XRef ID="20661" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247582" DB="Orphanet" />
              <XRef ID="C1997910" DB="MedGen" />
              <XRef ID="MONDO:0016602" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="65850" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="55843" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia, type II, adult-onset</ElementValue>
                <XRef ID="MONDO:0011326" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTLN2</ElementValue>
                <XRef Type="MIM" ID="603471" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia_II_Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Citrin Deficiency, Citrullinemia II, Urea Cycle Disorder, 2012</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="CN295299" DB="MedGen" />
              <XRef ID="MONDO:0011326" DB="MONDO" />
              <XRef Type="MIM" ID="603471" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="89115" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="72035" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">SLC25A13-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">SLC25A13-related disorder</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="26550" SubmissionDate="2013-09-24" DateLastUpdated="2013-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603859.0001_CITRULLINEMIA, TYPE II, NEONATAL-ONSET" title="SLC25A13, 4-BP DEL, 851GTAT_CITRULLINEMIA, TYPE II, NEONATAL-ONSET" />
        <ClinVarAccession Accession="SCV000026550" DateUpdated="2013-09-27" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-11-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Kobayashi et al. (1999) found that 9 patients with adult-onset type II citrullinemia (603471) were homozygous for a 4-bp (GTAT) deletion from nucleotide 851 in exon 9, predicting a frameshift and introduction of a stop codon at position 286, leading to premature termination of the protein. Three other patients were heterozygous for the mutation.</Attribute>
              <Citation>
                <ID Source="PubMed">10369257</ID>
              </Citation>
              <XRef DB="OMIM" ID="603471" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ohura et al. (2001) identified a child with neonatal-onset citrullinemia (605814) who was compound heterozygous for this mutation and an IVS11+1G-A mutation (603859.0002) in the SLC25A13 gene. The patient pursued a favorable clinical course, and all biochemical abnormalities normalized by the age of 12 months.</Attribute>
              <Citation>
                <ID Source="PubMed">11281457</ID>
              </Citation>
              <XRef DB="OMIM" ID="605814" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tamamori et al. (2002) reported a patient with neonatal-onset citrullinemia who was compound heterozygous for the 4-bp deletion and IVS11+1G-A. She had an unusual disease course with a worsening of liver function at age 6 months, ultimately requiring a living-related liver transplant at 10 months of age. She had normal growth and mental development at age 3 years. Tamamori et al. (2002) noted that the same genotype had been identified in a patient with the usual course of spontaneous remission (Ohura et al., 2001), suggesting that the severe phenotype was not due to the genotype.</Attribute>
              <Citation>
                <ID Source="PubMed">12424587</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">11281457</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <Name>SLC25A13, 4-BP DEL, 851GTAT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 851GTAT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603859.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">CITRULLINEMIA, TYPE II, NEONATAL-ONSET</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="26549" SubmissionDate="2013-09-24" DateLastUpdated="2013-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603859.0001_CITRULLINEMIA, TYPE II, ADULT-ONSET" title="SLC25A13, 4-BP DEL, 851GTAT_CITRULLINEMIA, TYPE II, ADULT-ONSET" />
        <ClinVarAccession Accession="SCV000026549" DateUpdated="2013-09-27" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-11-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Kobayashi et al. (1999) found that 9 patients with adult-onset type II citrullinemia (603471) were homozygous for a 4-bp (GTAT) deletion from nucleotide 851 in exon 9, predicting a frameshift and introduction of a stop codon at position 286, leading to premature termination of the protein. Three other patients were heterozygous for the mutation.</Attribute>
              <Citation>
                <ID Source="PubMed">10369257</ID>
              </Citation>
              <XRef DB="OMIM" ID="603471" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ohura et al. (2001) identified a child with neonatal-onset citrullinemia (605814) who was compound heterozygous for this mutation and an IVS11+1G-A mutation (603859.0002) in the SLC25A13 gene. The patient pursued a favorable clinical course, and all biochemical abnormalities normalized by the age of 12 months.</Attribute>
              <Citation>
                <ID Source="PubMed">11281457</ID>
              </Citation>
              <XRef DB="OMIM" ID="605814" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tamamori et al. (2002) reported a patient with neonatal-onset citrullinemia who was compound heterozygous for the 4-bp deletion and IVS11+1G-A. She had an unusual disease course with a worsening of liver function at age 6 months, ultimately requiring a living-related liver transplant at 10 months of age. She had normal growth and mental development at age 3 years. Tamamori et al. (2002) noted that the same genotype had been identified in a patient with the usual course of spontaneous remission (Ohura et al., 2001), suggesting that the severe phenotype was not due to the genotype.</Attribute>
              <Citation>
                <ID Source="PubMed">12424587</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">11281457</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <Name>SLC25A13, 4-BP DEL, 851GTAT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 851GTAT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603859.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CITRULLINEMIA, TYPE II, ADULT-ONSET</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="501065" SubmissionDate="2016-04-14" DateLastUpdated="2017-12-26" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="NM_014251.2:c.852_855delTATG|OMIM:603471" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000267504" DateUpdated="2017-12-26" DateCreated="2017-12-26" Type="SCV" Version="1" SubmitterName="Soonchunhyang University Bucheon Hospital, Soonchunhyang University Medical Center" OrgID="505765" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-03-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17880783</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19470249</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>East Asian</Ethnicity>
              <GeographicOrigin>South Korean</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">40</Age>
              <Age Type="maximum" age_unit="years">69</Age>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>reference population</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1663594" SubmissionDate="2018-04-09" DateLastUpdated="2016-12-06" DateCreated="2016-12-06">
        <ClinVarSubmissionID localKey="NM_014251.2:c.852_855del|OMIM:605814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000853101" DateUpdated="2016-12-06" DateCreated="2016-12-06" Type="SCV" Version="1" SubmitterName="SingHealth Duke-NUS Institute of Precision Medicine" OrgID="506534" OrganizationCategory="other" OrgAbbreviation="PRISM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-06-07">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3881284</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="645354" SubmissionDate="2018-09-19" DateLastUpdated="2018-12-16" DateCreated="2018-12-16">
        <ClinVarSubmissionID localKey="28526_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000331844" DateUpdated="2018-12-16" DateCreated="2018-12-16" Type="SCV" Version="4" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000331843" DateChanged="2019-08-06" Version="3">
            <Comment Type="MergeComment">SCV000331843 was merged into SCV000331844 to remove duplication.</Comment>
          </Replaced>
        </ReplacedList>
        <Classification DateLastEvaluated="2017-09-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23022256</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/ahdynye1/egl_classification_definitions_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="5" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="2" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="7" alternateAllele="-" referenceAllele="CATA" start="95818684" stop="95818687" variantLength="4" />
            <GeneLocation>NM_014251.2:Ex9</GeneLocation>
          </Location>
          <XRefList>
            <XRef DB="HGMD" ID="CD991947" />
            <XRef DB="dbSNP" ID="569808959" Type="rsNumber" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=SLC25A13</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>EGL005</SubmissionName>
          <SubmissionName>SUB4534263</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="784251" SubmissionDate="2019-02-01" DateLastUpdated="2019-05-27" DateCreated="2016-12-06">
        <ClinVarSubmissionID localKey="604965" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000470730" DateUpdated="2019-05-27" DateCreated="2016-12-06" Type="SCV" Version="3" SubmitterName="Illumina Laboratory Services, Illumina" OrgID="504895" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-04-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21424115</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12424587</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11281457</ID>
          </Citation>
          <Comment>The SLC25A13 c.852_855delTATG (p.Met285ProfsTer2) variant, also referred to in the literature as c.851_854del and c.851del4, is a frameshift variant that leads to premature truncation of the protein, and is one of the most common pathogenic variants in Japanese persons with citrin deficiency. Across a selection of available literature, the p.Met285ProfsTer2 variant has been identified in a homozygous state in 30 patients, in a compound heterozygous state in 27 patients, and in a heterozygous state in two patients in whom a second variant was not identified (Kobayashi et al. 1999; Ohura et al. 2001; Tamamori et al. 2002; Song et al. 2011). The p.Met285ProfsTer2 variant was absent from 127 controls and is reported at a frequency of 0.01515 in the Kinh in Ho Chi Minh City, Vietnam population of the 1000 Genomes Project. Based on the collective evidence and the potential impact of frameshift variants, the p.Met285ProfsTer2 variant is classified as pathogenic for citrin deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ICSL Variant Classification Criteria 09 May 2019</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/thsgk7t4/icsl_variant_classification_criteria_09_may_2019.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="7" alternateAllele="T" referenceAllele="TCATA" start="95818683" stop="95818687" variantLength="5" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5118208</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292632" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000007.13:g.95818685_95818688delATAC|OMIM:605814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163576" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95818685_95818688delATAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="41264" SubmissionDate="2022-06-28" DateLastUpdated="2022-10-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="NM_014251.2:c.851_854del|OMIM:603471" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000041264" DateUpdated="2022-10-01" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="BookShelf">NBK1181</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>851del4</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.851_854del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN295299" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11612813</SubmissionName>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1238771" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="2448586|MedGen:C1997910" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000646232" DateUpdated="2024-02-14" DateCreated="2017-12-26" Type="SCV" Version="9" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14680984</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27405544</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12512993</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23022256</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23067347</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26852511</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27347070</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27405544</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27577219</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27578510</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Met285Profs*2) in the SLC25A13 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC25A13 are known to be pathogenic (PMID: 10369257, 14680984, 27405544). This variant is present in population databases (rs569808959, gnomAD 0.5%). This premature translational stop signal has been observed in individual(s) with citrin deficiency (PMID: 10369257, 12512993, 23022256, 23067347, 26852511, 27347070, 27405544, 27577219, 27578510). It has also been observed to segregate with disease in related individuals. This variant is also known as c.851del4. ClinVar contains an entry for this variant (Variation ID: 225472). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95818684_95818687del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1997910" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2869024" SubmissionDate="2020-12-28" DateLastUpdated="2021-01-02" DateCreated="2021-01-02">
        <ClinVarSubmissionID localKey="NM_014251.3:c.852_855delTATG|Late-onset citrullinemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001453749" DateUpdated="2021-01-02" DateCreated="2021-01-02" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.852_855delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Late-onset citrullinemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8808661</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4987680" SubmissionDate="2022-07-15" DateLastUpdated="2022-07-17" DateCreated="2022-07-17">
        <ClinVarSubmissionID localKey="NM_014251.2:c.852_855delTATG|MedGen:C1863844" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002548484" DateUpdated="2022-07-17" DateCreated="2022-07-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21424115</ID>
          </Citation>
          <Comment>Variant summary: SLC25A13 c.852_855delTATG (p.Met285ProfsX2) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 0.00033 in 251422 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SLC25A13 causing Citrullinemia Type II (0.00033 vs 0.0011), allowing no conclusion about variant significance. c.852_855delTATG has been widely reported in the literature in multiple individuals affected with Citrullinemia Type II (example, Zong Song_2011). These data indicate that the variant is very likely to be associated with disease. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1863844" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11800792</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5462993" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_014251.3:c.852_855del|OMIM:603471;605814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002804401" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.852_855del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4984914" SubmissionDate="2023-02-19" DateLastUpdated="2023-02-25" DateCreated="2023-01-07">
        <ClinVarSubmissionID localKey="NM_014251.2:c.851_854del|OMIM:605814" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002546525" DateUpdated="2023-02-25" DateCreated="2023-01-07" Type="SCV" Version="2" SubmitterName="Genesolutions, Medical Genetics Institutes, Ho Chi Minh City, Vietnam" OrgID="508641" OrganizationCategory="laboratory" OrgAbbreviation="GS-MGI" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508964" SubmitterName="Hepatology Department, National Children’s Hospital" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">36599957</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.851_854del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11739646</SubmissionName>
          <SubmissionName>SUB12880035</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4924721" SubmissionDate="2022-05-16" DateLastUpdated="2023-03-04" DateCreated="2022-05-21">
        <ClinVarSubmissionID localKey="GDXSV:226872" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002512901" DateUpdated="2023-03-04" DateCreated="2022-05-21" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-02-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 26852511, 27779681, 23022256, 19470249, 17880783, 10369257, 27405544, 12512993, 27347070, 27577219, 29659898, 26858187, 29152073, 29651749, 30591617, 29961769, 16059747, 31620407, 31607264, 29625052, 31845334, 26689913, 33817322, 34426522, 33627582, 31589614, 32289814, 33763395, 33176737, 28981931, 33497767, 33611823)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:693881</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_104_20220504054205</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7696156" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="2234850|SLC25A13-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004116582" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The SLC25A13 c.852_855delTATG variant is predicted to result in a frameshift and premature protein termination (p.Met285Profs*2). This variant is commonly reported to be causative for citrin deficiency in Asian populations (e.g., Kobayashi et al. 1999. PubMed ID: 10369257, reported as 851del4; Lin et al. 2016. PubMed ID: 27405544, reported as c.851_854del4). Many other predicted loss-of-function variants in SLC25A13 have been reported in association with citrullinemia type 2 and/or neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) (ClinVar database; Human Gene Mutation Database, http://www.hgmd.cf.ac.uk/ac/index.php). We classify this variant as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855delTATG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">SLC25A13-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3968762" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="9e81b8b8c899dcb55460c8f339301b481a50e92b15df1e22f5a3899fe0466d33|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002020658" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.852_855del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8883143" SubmissionDate="2024-03-12" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="Huaihuafyyck2024_031" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004800868" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="Neonatal Disease Screening Center, Medical Genetics Center, Huaihua City Maternal and Child Health Care Hospital" OrgID="509482" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>PVS1+PM3_VS+PP1_M+PP4</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="pmc">PMC4544753</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Han</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">Huaihuafyyck2024A_003</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Miao</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">Huaihuafyyck2024A_011</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Miao</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">Huaihuafyyck2024A_023</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Miao</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">Huaihuafyyck2024A_026</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Han</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">Huaihuafyyck2024A_036</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.852_855del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14302371</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7856480" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_014251.3:c.852_855del|OMIM:603471" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004203602" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.852_855del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7856480" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1663594" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="41264" TraitType="Disease" MappingType="XRef" MappingValue="CN295299" MappingRef="MedGen">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8883143" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292632" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4987680" TraitType="Disease" MappingType="XRef" MappingValue="C1863844" MappingRef="MedGen">
        <MedGen CUI="C1863844" Name="Citrullinemia type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1238771" TraitType="Disease" MappingType="XRef" MappingValue="C1997910" MappingRef="MedGen">
        <MedGen CUI="C1997910" Name="Citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="26550" TraitType="Disease" MappingType="Name" MappingValue="CITRULLINEMIA, TYPE II, NEONATAL-ONSET" MappingRef="Alternate">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="784251" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3968762" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="26549" TraitType="Disease" MappingType="Name" MappingValue="CITRULLINEMIA, TYPE II, ADULT-ONSET" MappingRef="Preferred">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2869024" TraitType="Disease" MappingType="Name" MappingValue="Late-onset citrullinemia" MappingRef="Preferred">
        <MedGen CUI="C0268546" Name="Late-onset citrullinemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7696156" TraitType="Disease" MappingType="Name" MappingValue="SLC25A13-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="SLC25A13-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="645354" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5462993" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="501065" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4924721" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984914" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5462993" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2021-05-28">SCV001527691</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

